Same Molecule, Two Doses, Two Different Gallbladder Pictures

Gallstones appear in every list of GLP-1 side effects, usually with no number attached and never with the comparison that makes the number mean something. The labels have both, and reading five of them side by side turns up something none of them says on its own.

The same molecule, twice

Victoza, label revised 17 November 2025 — liraglutide, at diabetes doses:

"Cholelithiasis and cholecystitis In adult glycemic control trials of VICTOZA, the incidence of cholelithiasis was 0.3% in both VICTOZA-treated and placebo-treated patients."

Identical. No difference at all between drug and placebo.

Saxenda, revised 15 June 2026 — the same liraglutide, at the weight-loss dose:

"5.3 Acute Gallbladder Disease In SAXENDA clinical trials in adults, 2.2% of SAXENDA-treated patients reported adverse events of cholelithiasis versus 0.8% of placebo-treated patients."

Two point two against nought point eight. Same drug, same manufacturer, different dose and different population — and a signal that was invisible in one appears clearly in the other.

Saxenda reports the more serious endpoint too:

"The incidence of cholecystitis was 0.8% in SAXENDA-treated patients versus 0.4% in placebo-treated patients."

Victoza's own cardiovascular outcomes trial found something in between:

"In the LEADER trial [see Clinical Studies ( 14.3 )] , 3.1% of VICTOZA-treated patients versus 1.9% of placebo-treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis [see Adverse Re"

So even within one molecule the answer depends on which trial you read: no difference in the glycemic-control trials, 3.1% against 1.9% over the longer LEADER follow-up.

Ozempic's numbers run backwards

Ozempic, revised 10 June 2026:

"Cholelithiasis In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with OZEMPIC 0.5 mg and 1 mg, respectively."

One and a half percent at the LOWER dose, nought point four at the higher one. If gallstone risk simply tracked dose, that is the wrong way round.

It is worth being careful about what this shows. These are separate trial arms with different sizes and populations, not a dose-response experiment, and at these rates a handful of events moves the percentage a long way. What it does establish is that the simple story — more drug, more gallstones — is not what Ozempic's own label reports.

The tirzepatides sit lower

Mounjaro, revised 6 May 2026:

"In MOUNJARO placebo-controlled clinical trials in adults, acute gallbladder disease (cholelithiasis, biliary colic, and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients."

Trulicity, revised 10 August 2026:

"Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively."

Both under one percent. Note that Mounjaro's placebo arm reported zero — with rates this low, a placebo group of ordinary size can easily record none, which makes "0.6% versus 0%" look starker than the difference it describes.

Why rapid weight loss is the thread

The mechanism usually offered is not specific to this drug class: rapid weight loss itself raises gallstone risk, through changes in bile composition and reduced gallbladder emptying. It is documented after bariatric surgery and after very-low-calorie dieting.

That fits what the labels show. The one comparison in this set that holds the molecule constant and changes only the dose — Victoza against Saxenda — is also the comparison that holds everything constant except how much weight people lost.

What to do with this

Ask which number applies to your dose. Liraglutide at diabetes doses and liraglutide for weight loss produced different pictures in the same manufacturer's trials.

Know the symptom, not the statistic. Steady pain in the upper right abdomen, often after a fatty meal, sometimes into the right shoulder — that is the thing to report, and it does not behave like the ordinary GI side effects of the first weeks.

Do not read 0% as impossible. Mounjaro's placebo arm recorded zero events; that is a small-numbers artefact, not a claim that gallstones do not happen without the drug.

Check the revision date. Victoza's label is November 2025, Saxenda's June 2026, Trulicity's August 2026, Mounjaro's May 2026.

Where this comes from

Every figure is quoted from the manufacturer's own Structured Product Label on DailyMed, the National Library of Medicine's repository, using the manufacturer's label rather than a repackager's copy.

The mechanism paragraph is the standard explanation rather than a quotation, and is marked as such instead of being presented as sourced.

This is information, not medical advice. Whether gallbladder risk changes what you should take is a decision for you and your prescriber; what the labels give you is the number for your drug at your dose, rather than a shared one.